A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
Key claim: A clinical trial is evaluating whether sapablursen (an antisense oligonucleotide targeting TMPRSS6) can reduce phlebotomy frequency and improve quality of life in polycythemia vera patients by upregulating hepcidin to restrict iron-driven erythrocytosis.
Abstract
The main purpose of this study is to evaluate the efficacy of sapablursen in reducing the frequency of phlebotomy and in improving quality of life assessments in participants with polycythemia vera.
Why this matters
Sapablursen exemplifies a PV-specific therapeutic logic that does not generalize to other MPN subtypes: it exploits the disease’s pathognomonic iron-driven erythrocytosis by suppressing TMPRSS6 to raise hepcidin and restrict iron availability for erythropoiesis. This mechanism is orthogonal to JAK inhibition, interferon, and HDAC-targeted cytoreduction, and — alongside DISC-3405 — establishes the hepcidin/ACVR1 axis as an emerging PV-specific drug class. If effective, it could reshape PV natural history by reducing phlebotomy burden without cytoreductive toxicity.